Skip to content

Clinical Study on the Mechanism of Xinglou Chengqi Decoction in Treating Acute Ischemic stroke with Phlegm-Heat and Fu-Organ Excess Syndrome

Clinical Study on the Mechanism of Xinglou Chengqi Decoction in Treating Acute Ischemic stroke with Phlegm-Heat and Fu-Organ Excess Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073544
Enrollment
Unknown
Registered
2023-07-13
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral ischaemic stroke due to intracranial large artery atherosclerosis

Interventions

Xinglou Chengqi Decoction group:Taking Xinglou Chengqi Decoction plus or minus Chinese herbal formula granules
Buyang Huanwu Decoction group:Taking Buyang Huanwu Decoction plus or minus Chinese herbal formula granules
healthy control group:No intervention

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for phlegm-heat and fu-organ excess syndrome of cerebral infarction 1) Age = 45 years and = 80 years; 2) According to the diagnostic criteria of acute cerebral infarction and large artery atherosclerotic stroke subtypes in western medicine; 3) Onset admitted within 3 days; 4) According to the Diagnostic Scale for Syndrome Factors of Cerebral Infarction, it is necessary to meet the requirements that the scores of phlegm syndrome and heat syndrome are greater than 10 points, the score of qi deficiency syndrome is less than 4 points, and there is no defecation for more than 48 hours; 5) Patient or legal representative gave informed consent and signed informed consent. 2. Inclusion criteria of qi deficiency and blood stasis syndrome in cerebral infarction 1) Age = 45 years and = 80 years; 2) According to the diagnostic criteria of acute cerebral infarction and large artery atherosclerotic stroke subtypes in western medicine; 3) Onset admitted within 3 days; 4) According to the Diagnostic Scale for Syndrome Factors of Cerebral Infarction, it is consistent with qi deficiency syndrome greater than 10 points, blood stasis syndrome greater than 7 points, and phlegm syndrome and heat syndrome scores less than 4 points; 5) Patient or legal representative gave informed consent and signed informed consent. 3. Inclusion criteria for healthy controls 1) Age = 45 years and = 80 years; 2) Physical examination and routine hematuria stool test, blood glucose, blood lipid, liver and kidney function test, as well as chest radiography within 3 months, assessed that there were no substantial lesions in the heart, brain, liver, kidney, lung and other major organs, and routine physical examination demonstrated normal body weight (18 < BMI < 25); 3) Collect stool samples within 48 hours of enrollment; 4) According to the Diagnostic Scale for Syndrome Factors of Cerebral Infarction, the scores of each syndrome were less than 4 points; 5) Voluntarily join and cooperate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients taking antibiotics, prebiotics or probiotics within one month; 2) Identify that the cause of cerebral infarction is not related to atherosclerosis (such as arterial dissection, combined atrial fibrillation, rheumatic heart disease, valvular heart disease and other diseases that may cause embolism); 3) History of systemic diseases (e.g., liver cirrhosis, renal insufficiency, intestinal diseases including inflammatory bowel disease, Crohn 's disease, ulcerative colitis, postoperative gastrointestinal diseases, tumors, mental disorders, etc.); 4) Patients with unstable blood pressure and dysphagia; 5) Alcoholics.

Design outcomes

Primary

MeasureTime frame
TCM syndrome score;Blood lymphocyte subsets;Blood inflammatory factors;

Secondary

MeasureTime frame
NIHSS score;Metagenomics of fecal microbiota;Blood untargeted metabolomics;

Countries

China

Contacts

Public ContactDayong Ma

Dongzhimen Hospital, Beijing University of Chinese Medicine

a3153@bucm.edu.cn+86 134 8871 6630

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026